�
Over
the age of 75 years, manpower should no longer be screened for prostate
cancer the Crab, according to recommendations from the U.S. Preventive Services
Task Force published on August 5, 2008 in the Annals of
Internal Medicine.
Additionally, they indicate that younger workforce should talk over the
potential risks and benefits of the prostate-specific antigen (PSA)
treatment with their doctors earlier performing the test.
Prostate
cancer affects this small gland in the male procreative system. In
2007, approximately 218,890 workforce were diagnosed with
prostate gland cancer in the U.S.. One in six hands will invite this diagnosis
at some point in his life. Currently, screening is performed using
a digital rectal exam or the PSA test. While the PSA test has a higher
sensitivity and is more likely to detect cancer, these cancers are
normally in identical early stages and so take years to affect the man's
health. Often, cancers detected with this tests take more than 10 eld
to train hold.
The screening process, while relatively
standard, can be associated with some physical and psychological harms.
Physically, the man must undergo biopsies, and there is the opportunity for
unnecessary treatment. Psychologically, false positives may be
detected, leading to anxiety. The discourse of prostate cancer itself
can experience complications including urinary incontinence and impotence.
�However, early stage untreated cancers rarely cause any of
these
side effects -- meaning that, at a certain age, it is possible that man
is harmed by being screened for prostate gland cancer with few potential difference
benefits.
Men older than 75 in the U.S. have an average
anticipation of just about 10 days, and in this population, death is
more likely to come due to heart disease or stroke, rendering
cognition about prostate gland cancer status largely moot. Thanks to this,
screening for prostate gland cancer, according to the Task Force, provided
comparatively few health benefits while still preeminent to harm which was
mostly physical but part psychological when men ar 75 and older.
Men
younger than 75 can likewise have a life expectancy shorter than the adjacent
ten years as a result of chronic diseases. Individuals in this
population are likewise unlikely to benefit from screening.
For
younger men, they concluded that there is not sufficient evidence to
balance the risks and harms, so each private should assess his risks
separately.
The Task Force Chair, Ned Calonge, M.D., M.P.H.,
summarizes: "Because
many prostate cancers grow tardily, early catching may not benefit a
patient's health and in some cases may regular cause harm." He continues,
explaining current policies on the screening process: "We encourage manpower
younger than 75 to discuss with
their clinicians the potential--but uncertain--benefits and the possible
harms of getting the PSA test before they decide to be screened."
Nearly
one-third of all workforce in the U.S. over the age of 75 are having PSA
testing performed, according to current information. Most medical
organizations suggest that it is prudent to break screening when
an single has an average expectancy of less than 10 years, but this
is the number one explicit long time to be specified for this test. There are
presently deuce ongoing studies that will help clear up the potential difference
benefits of screening in men under 75: the National Cancer Institute's
(NCI) Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial and the European Study of Screening for
Prostate Cancer.
This Task force is an independent panel of experts in prevention and
primary maintenance, with a mission to conduct rigorous, impartial analyses of
the evidence for and against many clinical preventive services such as
screening, guidance, and preventive medications. for clinical
incumbrance services, the Task Force defines many of the gold standard
methods.
For clinicians, additional information john be set up on the Agency
for Health Care Research and Quality website� or AHRQ's National Guideline
Clearinghouse.
For men world Health Organization have been diagnosed with prostate cancer, information around
treatment john be establish on the effective health
care portion of the AHRQ internet site, describing effective health
care.
Screening for Prostate Cancer: U.S. Preventive Services Task
Force Recommendation Statement
U.S. Preventive Services Task Force
Annals Internal Medicine, 5 August 2008, Volume
149, Issue 3, Pages 185-191
Click
Here For Abstract
Written by Anna Sophia McKenney
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
